PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps3107
Abstract: TPS3107Background: CX-072 is a novel Probody therapeutic (PbTx) targeting PD-L1. PbTxs are fully recombinant antibody prodrugs designed to be converted to active antibodies by tumor-associated pr... read more here.
Keywords: probody; proclaim 001; trial assess; 001 first ... See more keywords